Compare BW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | IPHA |
|---|---|---|
| Founded | 1867 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 165.3M |
| IPO Year | 2015 | 2014 |
| Metric | BW | IPHA |
|---|---|---|
| Price | $6.28 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.00 | $5.75 |
| AVG Volume (30 Days) | ★ 4.2M | 35.0K |
| Earning Date | 05-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,062,388,000.00 | N/A |
| Revenue This Year | $41.58 | $180.36 |
| Revenue Next Year | $66.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.70 | $1.18 |
| 52 Week High | $22.03 | $2.71 |
| Indicator | BW | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 34.75 |
| Support Level | $4.57 | $1.67 |
| Resistance Level | $8.05 | $1.83 |
| Average True Range (ATR) | 0.45 | 0.10 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 14.78 | 15.24 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.